Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Many pharmaceutical firms' corporate plans for developing new asthma products that combine long-acting beta agonists with inhaled corticosteroids are not seriously affected by the recommendation of three FDA advisory committees to eliminate the asthma indication for single-entity LABA products

You may also be interested in...

New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products

Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol

FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma

Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.

Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD

Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts